Quanterix Corporation has announced the publication of a landmark study in the journal Nature, utilizing its ultra-sensitive Simoa p-Tau 217 assay for Alzheimer's disease research. The study, which has already been published, represents the largest population-based assessment to date, analyzing over 11,000 samples to provide new insights into the prevalence of Alzheimer's Disease Neuropathological Changes (ADNC). The research found that 30.4% of people aged 70 and above exhibit ADNC, with 10% of this population meeting current treatment eligibility criteria. The study also established key associations between sex, APOE genotype, and education level in the development of Alzheimer's pathology. These results offer critical data for public health planning and the future development of Alzheimer's treatments.